Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
– Expanded indication for ZYNRELEF now covers approximately 13 million procedures annually –
SAN DIEGO, Jan. 23, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (the “FDA”) has approved its supplemental New Drug Application (“NDA”) for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided. ZYNRELEF was previously approved for foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures in adults.
Related news for (HRTX)
- Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value
- Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile
- Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress
- Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
- Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025